Integra LifeSciences (NASDAQ:IART) Stock Rating Lowered by Zacks Research

Integra LifeSciences (NASDAQ:IART) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday, Zacks reports.

IART has been the subject of several other research reports. Citizens Jmp dropped their price target on shares of Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating for the company in a research report on Thursday, October 22nd. Wells Fargo & Company set a $13.00 target price on Integra LifeSciences and gave the stock an “equal weight” rating in a report on Thursday, October 22nd. Citigroup restated an “outperform” rating on shares of Integra LifeSciences in a research report on Thursday, October 22nd. Wall Street Zen lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Truist Financial set a $13.00 price target on Integra LifeSciences and gave the company a “hold” rating in a research report on Friday. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $16.12.

Integra LifeSciences Price Performance

IART opened at $11.99 on Monday. The company has a market capitalization of $932.50 million, a P/E ratio of 70.53 and a beta of 1.21. The firm’s fifty day moving average price is $15.11 and its two-hundred day moving average price is $14.10. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.49.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. The business had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. During the same quarter in the prior year, the company posted ($0.07) EPS. On average, equities research analysts expect that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently bought and sold shares of the business. Paradigm Capital Management Inc. NY bought a new position in Integra LifeSciences in the 2nd quarter valued at $61,766,000. Wellington Management Group LLP grew its holdings in shares of Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock worth $26,241,000 after purchasing an additional 160,814 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares during the last quarter. Glenmede Trust Co. NA increased its stake in shares of Integra LifeSciences by 27.4% in the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after buying an additional 211,774 shares in the last quarter. Finally, Access Investment Management LLC increased its stake in shares of Integra LifeSciences by 39.5% in the third quarter. Access Investment Management LLC now owns 564,982 shares of the life sciences company’s stock valued at $9,198,000 after buying an additional 159,980 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.